These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26685070)

  • 21. [Variability in the clinical presentation of Pompe disease: development following enzyme replacement therapy].
    Ley-Martos M; Salado-Reyes MJ; Espinosa-Rosso R; Solera-García J; Jiménez-Jiménez L
    Rev Neurol; 2015 Nov; 61(9):416-20. PubMed ID: 26503317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
    Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
    Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.
    Chien YH; Lee NC; Chen CA; Tsai FJ; Tsai WH; Shieh JY; Huang HJ; Hsu WC; Tsai TH; Hwu WL
    J Pediatr; 2015 Apr; 166(4):985-91.e1-2. PubMed ID: 25466677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Kazi ZB; Desai AK; Troxler RB; Kronn D; Packman S; Sabbadini M; Rizzo WB; Scherer K; Abdul-Rahman O; Tanpaiboon P; Nampoothiri S; Gupta N; Feigenbaum A; Niyazov DM; Sherry L; Segel R; McVie-Wylie A; Sung C; Joseph AM; Richards S; Kishnani PS
    Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
    Park JS; Kim HG; Shin JH; Choi YC; Kim DS
    Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
    Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
    Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early cognitive development in children with infantile Pompe disease.
    Spiridigliozzi GA; Heller JH; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2012 Mar; 105(3):428-32. PubMed ID: 22217428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Ebbink BJ; Aarsen FK; van Gelder CM; van den Hout JM; Weisglas-Kuperus N; Jaeken J; Lequin MH; Arts WF; van der Ploeg AT
    Neurology; 2012 May; 78(19):1512-8. PubMed ID: 22539577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive Development in Infantile-Onset Pompe Disease Under Very Early Enzyme Replacement Therapy.
    Lai CJ; Hsu TR; Yang CF; Chen SJ; Chuang YC; Niu DM
    J Child Neurol; 2016 Dec; 31(14):1617-1621. PubMed ID: 27655474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease).
    Rohman PJ; Scott E; Richfield L; Ramaswami U; Hughes DA
    J Obstet Gynaecol Res; 2016 Oct; 42(10):1263-1271. PubMed ID: 27384519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy.
    Avula S; Nguyen TM; Marble M; Lilje C
    Echocardiography; 2017 Apr; 34(4):621-624. PubMed ID: 28266734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition.
    Remiche G; Herbaut AG; Ronchi D; Lamperti C; Magri F; Moggio M; Bresolin N; Comi GP
    Eur Neurol; 2012; 68(2):75-8. PubMed ID: 22760201
    [No Abstract]   [Full Text] [Related]  

  • 37. Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months.
    Schneider I; Hanisch F; Müller T; Schmidt B; Zierz S
    Wien Med Wochenschr; 2013 Jan; 163(1-2):40-4. PubMed ID: 23160972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report.
    Rovelli V; Zuvadelli J; Piotto M; Scopari A; Dionigi AR; Ercoli V; Paci S; Cefalo G; Salvatici E; Banderali G
    Ital J Pediatr; 2022 Mar; 48(1):48. PubMed ID: 35346323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
    Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
    J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.